AGIO vs NVO

Agios Pharmaceuticals Inc.'s potential for 10x growth has significantly improved since the last analysis. The most material change is the **absence of any mention of a securities fraud investigation**, a critical red flag cited previously. Furthermore, PYRUKYND (mitapivat) received FDA approval in December 2025 and demonstrated strong 86% YoY revenue growth in Q4 2025, validating its commercial po...

Novo Nordisk (NVO) remains a formidable pharmaceutical giant, leading in diabetes and obesity care with its dominant GLP-1 franchise. The company is financially robust, boasts significant proprietary assets, and has a strategic vision for new therapeutic applications and AI integration. Recent FDA approvals for Wegovy HD and oral Wegovy are positive developments, enhancing its product portfolio. H...